The cerebrospinal fluid in multiple sclerosis: far beyond the bands

• Autor(a) principal: Domingues,Renan Barros
• Data de Publicação: 2017
• Outros Autores: Fernandes,Gustavo Bruniera Peres, Leite,Fernando Brunale Vilela de Moura, Tilbery,Charles Peter, Thomaz,Rodrigo Barbosa, Silva,Gisele Sampaio, Mangueira,Cristóvão Luis Pitangueira, Soares,Carlos Augusto Senne
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Einstein (São Paulo)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082017000100100
• topic: Multiple sclerosis; Cerebrospinal fluid; Biomarkers; Chemokine CXCL13; Fetuins; Neurofilament proteins

ABSTRACT The cerebrospinal fluid analysis has been employed for supporting multiple sclerosis diagnosis and ruling out the differential diagnoses. The most classical findings reflect the inflammatory nature of the disease, including mild pleocytosis, mild protein increase, intrathecal synthesis of immunoglobulin G, and, most typically, the presence of oligoclonal bands. In recent years, new biomarkers have emerged in the context of multiple sclerosis. The search for new biomarkers reflect the need of a better evaluation of disease activity, disease progression, and treatment efficiency. A more refined evaluation of disease and therapy status can contribute to better therapeutic choices, particularly in escalation of therapies. This is very relevant taking into account the availability of a greater number of drugs for multiple sclerosis treatment in recent years. In this review, we critically evaluate the current literature regarding the most important cerebrospinal fluid biomarkers in multiple sclerosis. The determination of biomarkers levels, such as chemokine ligand 13, fetuin A, and mainly light neurofilament has shown promising results in the evaluation of this disease, providing information that along with clinical and neuroimaging data may contribute to better therapeutic decisions.